Reports Q4 revenue $0, consensus $220,000. "2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "This progress has positioned us for future milestones in 2023, including our anticipated initiation of a Phase 2a trial with RPT193 in asthma this quarter and a clinical data update from our ongoing Phase 2 trial of FLX475 in multiple cancer indications, which we are targeting for the second half of this year. For our Phase 2b trial of RPT193 in atopic dermatitis, we now expect topline results in mid-2024 due to recent slower than expected patient enrollment as we did not see the seasonal uptick that we anticipated. Our cash position is strong and we expect it to provide runway into mid-2025, well beyond the expected data readout."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAPT:
- Rapt Therapeutics Craters as Testing Proves a Challenge
- RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
- Rapt Therapeutics says $2M of cash held at Silicon Valley Bank
- RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
- 2 “Strong Buy” Small Cap Stocks That Can Rip Higher in 2023